Fj Capital Management Llc increased Home Bancorp Inc (HBCP) stake by 1.52% reported in 2017Q2 SEC filing. Fj Capital Management Llc acquired 9,900 shares as Home Bancorp Inc (HBCP)’s stock declined 3.73%. The Fj Capital Management Llc holds 660,600 shares with $28.09M value, up from 650,700 last quarter. Home Bancorp Inc now has $324.04M valuation. The stock increased 1.54% or $0.66 during the last trading session, reaching $43.52. About 7,565 shares traded. Home Bancorp, Inc. (NASDAQ:HBCP) has risen 24.80% since December 7, 2016 and is uptrending. It has outperformed by 8.10% the S&P500.
The stock of Global Blood Therapeutics Inc. (NASDAQ:GBT) hit a new 52-week high and has $46.02 target or 5.00% above today’s $43.83 share price. The 5 months bullish chart indicates low risk for the $1.92 billion company. The 1-year high was reported on Dec, 7 by Barchart.com. If the $46.02 price target is reached, the company will be worth $95.75 million more. The stock increased 8.75% or $3.525 during the last trading session, reaching $43.825. About 805,074 shares traded. Global Blood Therapeutics Inc. (NASDAQ:GBT) has risen 43.51% since December 7, 2016 and is uptrending. It has outperformed by 26.81% the S&P500.
Among 2 analysts covering Home Bancorp (NASDAQ:HBCP), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Home Bancorp had 4 analyst reports since August 13, 2015 according to SRatingsIntel. Raymond James initiated it with “Outperform” rating and $29 target in Wednesday, September 30 report. Zacks downgraded the shares of HBCP in report on Thursday, August 13 to “Buy” rating. Sandler O’Neill maintained the stock with “Hold” rating in Wednesday, October 18 report. Raymond James downgraded the shares of HBCP in report on Wednesday, July 26 to “Market Perform” rating.
Fj Capital Management Llc decreased National Gen Hldgs Corp (NASDAQ:NGHC) stake by 64,400 shares to 45,300 valued at $957,000 in 2017Q2. It also reduced Charter Finl Corp Md (NASDAQ:CHFN) stake by 23,300 shares and now owns 149,000 shares. Franklin Finl Network Inc was reduced too.
Analysts await Global Blood Therapeutics Inc. (NASDAQ:GBT) to report earnings on March, 12. They expect $-0.73 earnings per share, up 1.35% or $0.01 from last year’s $-0.74 per share. After $-0.66 actual earnings per share reported by Global Blood Therapeutics Inc. for the previous quarter, Wall Street now forecasts 10.61% negative EPS growth.
Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders. The company has market cap of $1.92 billion. The Company’s lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. It currently has negative earnings. The firm is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities.
Among 5 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Global Blood Therapeutics had 8 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was initiated by JP Morgan with “Overweight” on Wednesday, January 4. Cowen & Co initiated the shares of GBT in report on Tuesday, September 8 with “Outperform” rating. Wedbush maintained Global Blood Therapeutics Inc. (NASDAQ:GBT) on Tuesday, October 25 with “Outperform” rating. Morgan Stanley initiated Global Blood Therapeutics Inc. (NASDAQ:GBT) on Tuesday, September 8 with “Overweight” rating. On Tuesday, September 8 the stock rating was initiated by Wedbush with “Outperform”. The firm earned “Neutral” rating on Tuesday, September 8 by Goldman Sachs. Empire maintained it with “Buy” rating and $58 target in Friday, June 17 report.